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gastric remnantDear Editor,
Hepatoid adenocarcinoma (HAC) is a rare malignant
neoplasm, and the incidence rate in Taiwan is 0.22% [1].
This letter to the editor describes a gastric mass lesion from
gastric remnant which was diagnosed as HAC.
An 83-year-old man was admitted with the presentation
of melena and loss of 7 kg of body weight in 5 months. He
had received distal gastrectomy with Billroth-II recon-
struction for duodenal ulcer bleeding 30 years previously.
He had habitual consumption of alcohol, but had no sero-
logical evidence of a hepatitis B or C infection. Esoph-
agogastroduodenoscopy revealed a mass at the gastric side
of the stoma with partial outlet obstruction (Figure 1A).
The computed tomography (Figure 1B) images disclosed the
focal thickening of the gastric wall and several liver tumors.
Laboratory examination showed an elevated alpha-
fetoprotein (AFP) level (64,876 ng/mL) and normal carci-
noembryonic antigen level (5.4 ng/mL). Echo-guided fineFigure 1. (A) Esophagogastroduodenoscopy reveals an ulcerative
tomography of the abdomen reveals multiple heterogeneous hepati
(D) hepatic tissue reveals positive staining of AFP. AFPZ alpha-fet
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and immunohistochemical (IHC) staining of both gastric and
hepatic tissues (Figures 1C and 1D) were positive for AFP,
hepatocyte paraffin antigen 1 (Hep-Par 1), and epithelial
marker cytokeratin (CK) 19, and were negative for CK7 and
CK20. The final diagnosis was HAC of the gastric remnant
with liver metastasis (cT3N3M1, Stage IV). After anemia was
corrected, the patient received feeding jejunostomy for
nutrition support but refused chemotherapy. Written
informed consent was obtained from the patient for pub-
lication of this report and any accompanying images.
It has been shown that gastric remnant after partial
gastrectomy increases the risk of gastric malignancy, and
partial gastrectomy with Billroth-II reconstruction is one of
the risk factors [2]. Variable types of malignancy have been
reported, but the development of HAC from gastric
remnant is quite rare. According to a systemic review [3],
approximately 83.9% of HAC arises from the stomach andprotruding mass at the gastric side of the stoma. (B) Computed
c tumors. Immunohistochemical staining of both (C) gastric and
oprotein.
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Letter to the Editor 483the mean age is 63.0 12.8 years. The median survival is 12
months (range from 1.2 months to 66 months) [4] but could
be prolonged to 21.9 months under chemotherapy [1]. The
most frequent distant metastasis site is the liver, followed
by the lymph nodes and the lungs. HAC can be classified as
AFP-producing and non-AFP-producing subtypes. Elevated
serum AFP can be detected in 84.8% of HAC cases, and more
than one half of these cases have positive AFP staining in
tumor tissue [4]. AFP level > 300 ng/mL is a poor prognostic
factor, and it correlates with higher possibility of metas-
tasis [5]. Endoscopy is an important tool to find the major
HAC lesion in the gastrointestinal tract, especially the
stomach. IHC stain can offer information in distinguishing
between hepatocellular carcinoma (HCC) and HAC. Mostly,
AFP and Hep-Par 1 stains are both positive in HCC and HAC.
CK19 is almost always positive in HAC but very low in HCC.
By contrast, positive CK7 and CK20 suggest HCC diagnosis
because of the low proportions of positive CK20 and CK7
stains in HAC [4]. HAC arose from adenocarcinoma with
intestinal phenotype, and the hepatoid component of it is
related to reduced CDX2 expression. The treatment of HAC
is the same as other subtypes of gastric adenocarcinoma
with curative or palliative surgery and adjuvant chemo-
therapy (fluorouracil based), which differs from the treat-
ment for HCC.
In conclusion, IHC stain is crucial to differentiate be-
tween HAC and HCC. This malignancy needs to be kept in
mind by clinicians, especially in regions where the preva-
lence of HCC is high.
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